ADPKD

You have accessRestricted Access
To Add Weight to Overweight
Maatje D.A. van Gastel and Esther Meijer

CJASN June 2021, 16 (6) 850-852; DOI: https://doi.org/10.2215/CJN.04150321

Add to Selected Citations
Open Access
Overweight and Obesity and Progression of ADPKD
Kristen L. Nowak, Cortney Steele, Berenice Gitomer, Wenchyi Wang, John Ouyang and Michel B. Chonchol

CJASN June 2021, 16 (6) 908-915; DOI: https://doi.org/10.2215/CJN.16871020

Add to Selected Citations
Open Access
A Patient Perspective on Genetic Testing for ADPKD
Dwight Odland

CJASN May 2021, 16 (5) 671-673; DOI: https://doi.org/10.2215/CJN.14051119

Add to Selected Citations
You have accessRestricted Access
Patients with Protein-Truncating PKD1 Mutations and Mild ADPKD
Matthew B. Lanktree, Elsa Guiard, Pedram Akbari, Marina Pourafkari, Ioan-Andrei Iliuta, Syed Ahmed, Amirreza Haghighi, Ning He, Xuewen Song, Andrew D. Paterson, Korosh Khalili and York P.C. Pei

CJASN March 2021, 16 (3) 374-383; DOI: https://doi.org/10.2215/CJN.11100720

Add to Selected Citations
You have accessRestricted Access
Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression
Judith E. Heida, Ron T. Gansevoort, A. Lianne Messchendorp, Esther Meijer, Niek F. Casteleijn, Wendy E. Boertien, Debbie Zittema and on behalf of the DIPAK Consortium

CJASN February 2021, 16 (2) 204-212; DOI: https://doi.org/10.2215/CJN.10470620

Add to Selected Citations
You have accessRestricted Access
Long-Term Safety of Tolvaptan in ADPKD
Dipal M. Patel and Neera K. Dahl

CJASN January 2021, 16 (1) 3-5; DOI: https://doi.org/10.2215/CJN.17981120

Add to Selected Citations
Open Access
Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst, Ron T. Gansevoort, Ronald D. Perrone, Jennifer Lee, Molly E. Hoke, Alvin Estilo and Olga Sergeyeva

CJASN January 2021, 16 (1) 48-58; DOI: https://doi.org/10.2215/CJN.10250620

Add to Selected Citations
Open Access
Preimplantation Genetic Testing for Monogenic Kidney Disease
Rozemarijn Snoek, Marijn F. Stokman, Klaske D. Lichtenbelt, Theodora C. van Tilborg, Cindy E. Simcox, Aimée D.C. Paulussen, Jos C.M.F. Dreesen, Franka van Reekum, A. Titia Lely, Nine V.A.M. Knoers, Christine E.M. de Die-Smulders and Albertien M. van Eerde

CJASN September 2020, 15 (9) 1279-1286; DOI: https://doi.org/10.2215/CJN.03550320

Add to Selected Citations
You have accessRestricted Access
Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan
Matteo Bargagli, Nasser A. Dhayat, Manuel Anderegg, Mariam Semmo, Uyen Huynh-Do, Bruno Vogt, Pietro Manuel Ferraro and Daniel G. Fuster

CJASN July 2020, 15 (7) 1007-1014; DOI: https://doi.org/10.2215/CJN.13861119

Add to Selected Citations
You have accessRestricted Access
A Post Hoc Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials
Susan E. Shoaf, John Ouyang, Olga Sergeyeva, Alvin Estilo, Hui Li and Deborah Leung

CJASN May 2020, 15 (5) 643-650; DOI: https://doi.org/10.2215/CJN.08170719

Add to Selected Citations

Main menu

User menu

Search

ADPKD

Pages

Articles

Information for Authors

About

Journal Information

More Information